share_log

Short Interest in Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) Expands By 30.3%

Short Interest in Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) Expands By 30.3%

對創新制藥公司(OTCMKTS: IPIX)的空頭興趣擴大了30.3%
kopsource ·  2023/04/20 04:43

Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX – Get Rating) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 620,700 shares, an increase of 30.3% from the March 15th total of 476,200 shares. Based on an average daily volume of 738,300 shares, the short-interest ratio is presently 0.8 days.

創新制藥公司(OTCMKTS: IPIX — 獲取評級)是3月份空頭利息大幅增加的目標。截至3月31日,空頭利息總額爲62.07萬股,較3月15日的476,200股增加了30.3%。根據738,300股的平均每日交易量,目前的空頭利率爲0.8天。

Innovation Pharmaceuticals Stock Down 10.0 %

創新制藥股下跌10.0%

Shares of OTCMKTS:IPIX traded down $0.00 during midday trading on Wednesday, hitting $0.02. The stock had a trading volume of 203,046 shares, compared to its average volume of 546,743. The stock has a 50 day moving average price of $0.02 and a two-hundred day moving average price of $0.02. Innovation Pharmaceuticals has a 1 year low of $0.01 and a 1 year high of $0.06.

週三午盤交易中,OTCMKTS: IPIX的股價下跌了0.00美元,觸及0.02美元。該股的交易量爲203,046股,而平均成交量爲546,743股。該股的50天移動平均價格爲0.02美元,200天移動平均線價格爲0.02美元。創新制藥的1年低點爲0.01美元,爲1年高點0.06美元。

Get
獲取
Innovation Pharmaceuticals
創新制藥
alerts:
警報:

About Innovation Pharmaceuticals

關於創新制藥

(Get Rating)

(獲取評級)

Innovation Pharmaceuticals, Inc is a clinical stage biotechnology company. It engages in developing therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The firm's lead cancer compound, Kevetrin, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers.

創新制藥公司是一家臨牀階段的生物技術公司。它致力於開發具有抗感染、腫瘤、抗炎和皮膚病學應用的療法。該公司的主要癌症化合物Kevetrin是一種抗癌藥物,已在臨牀前研究中證明了調節p53途徑和攻擊癌症的能力。

Read More

閱讀更多

  • Get a free copy of the StockNews.com research report on Innovation Pharmaceuticals (IPIX)
  • ASML Reports Massive Growth, Management Points To Sluggish 2023
  • Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
  • Mullen Automotive: Is The Bloom Off The Rose?
  • Diversified Abbott Laboratories Could Reverse And Move Higher
  • Okta Reversal In Progress While Catalysts Approach
  • 免費獲取 StockNews.com 關於創新制藥 (IPIX) 的研究報告的副本
  • ASML報告了大規模增長,管理層指出2023年表現疲軟
  • 分析師 Boost 會讓洛克希德·馬丁公司的股價上漲、上漲和下跌嗎?
  • Mullen Automotive:是玫瑰花的嗎?
  • 多元化的雅培實驗室可能會逆轉並走高
  • 催化劑接近時Okta的逆轉正在進行中

Receive News & Ratings for Innovation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

接收創新制藥日報的新聞和收視率 -在下面輸入您的電子郵件地址,即可通過Marketbeat.com的免費每日電子郵件時事通訊接收Innovation Pharmicals及相關公司最新新聞和分析師評級的簡明每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論